MediWound

MDWDApproved

MediWound is a commercial-stage biopharmaceutical company specializing in advanced wound care and burn management. Its lead product, NexoBrid, is a topically administered, botanical proteolytic enzyme approved for the rapid and selective removal of eschar in deep partial- and full-thickness thermal burns. The company leverages its proprietary enzymatic technology platform to develop novel therapeutics for severe burns and other hard-to-heal wounds, aiming to improve patient outcomes and reduce healthcare costs. MediWound's strategy involves expanding the indications for its existing products and advancing its pipeline through clinical development and strategic partnerships.

Market Cap

$217.9M

Employees

50-100

Focus

Biotech

MDWD · Stock Price

USD 16.96+3.45 (+25.54%)

Historical price data

AI Company Overview

Technology Platform

Proprietary enzymatic technology platform based on proteolytic enzymes derived from bromelain, designed for selective debridement and tissue repair in severe wounds.

Pipeline Snapshot

11 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
NexoBrid + Gel Vehicle	Thermal Burns	Phase 3
NexoBrid	Thermal Burns	Phase 3
EscharEx (EX-03) + Placebo (Gel vehicle)	Venous Leg Ulcer (VLU)	Phase 3
DGD	Burn	Phase 3
EscharEx (5% EX-02 formulation) + Gel Vehicle + Non-surgical standard of care (N...	Venous Leg Ulcer	Phase 2

Funding History

Total raised: $58M

IPO$35MUndisclosedFeb 6, 2014

Series B$15MPontifaxJun 15, 2010

Series A$8MPontifaxJun 15, 2007

FDA Approved Drugs

NEXOBRIDBLADec 28, 2022

Opportunities

The recent FDA approval of NexoBrid opens the large U.S.

burn care market.

Expanding into chronic wound care with EscharEx represents a significantly larger addressable market.

Further lifecycle management of NexoBrid for pediatric use and new burn indications provides near-term growth avenues.

Risk Factors

Commercial execution risk in the competitive U.S.

market is high.

Clinical development risks remain for EscharEx.

The company's financial sustainability depends on successful product launches and may require additional capital.

Reimbursement challenges could hinder market adoption.

Competitive Landscape

Competes against surgical debridement (standard of care) and collagenase-based products (e.g., Santyl) in burns. In chronic wounds, faces competition from advanced wound dressings and other debriding agents. Differentiation is based on enzymatic selectivity, speed of action, and potential to improve clinical outcomes and reduce costs.